Endo & Mallinckrodt Pharmaceuticals to Form a Combine Entity with $6.7B Cash-and-Stock
Shots:
- Mallinckrodt & Endo to combine their generic pharmaceuticals & Endo’s sterile injectables businesses, later separating the unit, with combined company headquartered in Dublin, Ireland & Endo operating as Mallinckrodt’s subsidiary
- As per the deal, Endo shareholders will receive $80M in cash & own 49.9% of the combined company, while Mallinckrodt shareholders will hold 50.1%, with a $6.7B implied pro forma enterprise value. Combined entity will be listed on NYSE following closing in H2’25
- Merged product portfolio will comprise branded generics incl. Xiaflex, Acthar Gel, Terlivaz, Supprelin LA & Aveed, plus the combined entity will operate 17 manufacturing sites, 30 distribution centers & ~5,700 employees at closing
Ref: Mallinckrodt | Image: Mallinckrodt & Endo
Related News:- Sun Pharma to Acquire Checkpoint Therapeutics For ~$355M
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
